AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.
Source: MarketWatch
Wednesday, 15. January 2025
Share:
12. February 2024 14:09
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
